1. Innovating Life Changing Technologies™ November 2014
Onciomed Company Profile
Innovations in Obesity &
Metabolic Technologies™
Dr. Raj Nihalani, Founder & CEO
15375 Barranca Parkway A101
Irvine, California, USA 92618
www.onciomed.com
Devices mentioned in this document are not approved by the US FDA and are not available for commercial use in the US.

2. Innovating Life Changing Technologies™ November 2014
Onciomed: What we do
Onciomed, Inc. is a clinical stage medical device company
with a novel, minimally invasive, reversible, medical implant
which imitates gastric surgery without cutting and removing
portion of the stomach. The device, the Gastric Vest System™
(GVS), is intended for treatment of obesity and diabetes.
Funding Need
$5 Million currently sought followed by $25 Million.
Financing to date = $1.5 Million + $2 Million committed
Market Size
Obesity: #1 preventable cause of death in the US.
 $200+ Billion global market
 $139 Billion US market by 2017
 14 Million obese patients eligible for Medicare
reimbursement
Team
Onciomed, Inc. is led by Dr. Raj Nihalani
 17 years of experience in medical device industry
 Over 20 patents applied/pending
 Expertise in M&A, corporate development, clinical
trials and regulatory approval
 Team of top notch surgeons identified
See: www.onciomed.com
Problems & Solutions
Challenges with current options:
 Drugs and appetite suppressants are not effective
 Maintaining durable weight loss is difficult
 Gastric surgery is complex and has potential for
complications that include life threatening bleeds
and leaks of stomach contents
 Vitamin depletion due to permanent removal of
stomach and parts of intestine
 Surgical options are non-reversible
Onciomed’s novel restrictive obesity technology is:
 A next-generation medical device
 Designed to solve problems described above
 Reversible
Uses biocompatible materials that have a long history of in-human
use
Patents & Milestones Reached
 Product designed & developed, ready for human use
 Animal Feasibility Study completed
 Proof of Concept in Human completed
 Procedure time 30-40 min, minimally invasive
 3 US issued patents, 2 Int’l issued (Israel, China)
 20 patents pending
 5 EU sites and 5 Latin America sites identified
 20 clinical trial patients identified in Latin America
(IRB approved)
 Management team in place
 Key opinion leaders, bariatric surgeons and hospitals
identified for clinical trials and prospective purchase
 European major distributors identified
Milestones Following Funding
Months Milestones
3-9 Implant 30-50 patients in Latin America
9-15 Initiate and implant 30-50 patients in EU
15-20 EU – CE Mark preparation and approval
Identify 20 US clinical sites
20-36 Commercialization preparation in EU and
Asia
Raise additional capital (up to US$30M)
Implant 100 patients in US at 20 sites
36-48 Commercialization in EU and ASIA
Implant additional 100 patients in the US at
20 sites
Explore EXIT opportunities
Exit Strategy
Our technology not only enables large medical device and life
science corporations to enter the obesity space, but also
allows them to penetrate and dominate the $160 Billion
obesity & diabetes market with our disruptive technology.
Position the company for exit following EU commercialization
status in 36-48 months.
History of Gastric Band: Valued over $1 Billion
Legal Representation
Corporate: STRADLING YOCCA CARLSON & RAUTH
Intellectual Property: SNELL & WILMER
Dr. Raj Nihalani, CEO of Onciomed, Inc.
raj@onciomed.com (714)658-3039 www.onciomed.com
15375 Barranca Parkway A101
Irvine, California, USA 92618
Innovating Life Changing Technologies ™ www.onciomed.com

3. Innovating Life Changing Technologies™ November 2014
Dr. Jaime Ponce is highly experienced with the adjustable laparoscopic
procedure. He was a principal investigator for the FDA trial with the Lap-
Band® and the Realize™ Band
Dr. Jaime Ponce
2013 President - American Society
for Metabolic and Bariatric Surgery
(ASMBS))
Chair: Department of Laparoscopic & Bariatric Surgery-Ruby Hall Clinic, Pune
Laparoscopic gastrointestinal surgery
Bariatric Surgery for Obesity
Dr. Shashank Shah
President Obesity Surgical
Society of India
Dr. Ramos serves as the Director General of Surgery at the Advanced Center of
Obesity and Metabolic Surgery (Gastro Obeso Center,) in Sao Paolo, Brazil.
ASMBS faculty member
Dr. Almino Cardoso Ramos
President Brazilian Obesity Society
Dr. Ashutosh Kaul
New York Chapter President,
ASMBS
Director Minimally Invasive surgery & Robotic Surgery,
Fellowship Director Institute for Minimally Invasive Surgery, NY.
2012 Program Director General Surgery Residency Program
Dr. Manoel Galvao Neto
Digestive Surgery and
Endoscopy
Currently he operates with Dr. Almino Ramos at the Advanced Center of Obesity
and Metabolic Surgery (Gastro Obeso Center,) in Sao Paolo, Brazil.
Dr. Flavia Soto
Bariatric Surgery
Ex Fellow Cleveland Clinic
Dr. Alper Celik
Metabolic Surgery Unit of
Turkey
Dr. Anir Gupta
Bariatric Surgery
Merriata, OH
Dr. Roberto Rumbaut
Bariatric Surgeon
Monterrey, Mexico
Dr. Chih-Kun Huang
Bariatric Surgeon,
Taiwan
Dr. Jayashree Todkar
Bariatric Surgeon Pune,
India
Dr. Elliott Goodman
Beth Israel Medical Center
Department of Surgery
Dr. Kazu Kasama
University of Tokyo
Scientific Advisory Board & Key Opinion Leaders
15375 Barranca Parkway A101
Irvine, California, USA 92618
Innovating Life Changing Technologies ™ www.onciomed.com